Foley Hoag LLP has announced the recruitment of Lance Shea as a partner in its Food and Drug Administration practice based in Washington, D.C. The legal firm expressed that Shea will bring extensive experience to his new role, particularly in the interface between science and law, with a specific emphasis on the pharmaceuticals and medical device sectors.
Shea’s practice will principally involve guiding clients through the complexities of securing and protecting marketing exclusivity and market share for medical products. This encompasses addressing regulatory approval challenges and advising on advertising claims—a critical area as the FDA continues to evolve its policies in response to scientific advancements and market dynamics.
Prior to joining Foley Hoag, Shea was a part of BakerHostetler, where he honed his expertise in the regulatory landscape surrounding drugs and medical devices. This move is anticipated to bolster Foley Hoag’s capabilities in navigating the intricacies of FDA regulations, a field that remains under intense scrutiny from both industry stakeholders and regulatory bodies.
This strategic hire underscores Foley Hoag’s commitment to expanding its footprint in the realm of FDA regulatory law, an area of increasing importance for clients seeking to adapt to a rapidly shifting legal and regulatory environment. More details about Shea’s transition can be found in the official announcement by the firm on Foley Hoag’s website.
Further insights into this development were highlighted in Bloomberg Law’s report on the appointment, which provides a comprehensive overview of his responsibilities and the role’s significance within the context of the firm’s broader strategic objectives. This appointment not only enhances Foley Hoag’s regulatory practice but also aligns with market trends demanding more nuanced expertise in FDA regulatory processes.